Delivery Order SPE2DB22D1106-SPE2DB25FFCQ4
- Not listed
- The Defense Logistics Agency awarded a $4,983.09 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,779.72 for 90 tablets of Gemtesa 75 mg on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency has awarded a delivery order valued at $10,816.44 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $8,009.57 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity). This is a firm fixed-price, non-set-aside contract with a completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was competitively selected...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $7,558.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The contract was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a $48,882.83 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) with a performance location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-asides and carries an ultimate completion date of August 18, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $7,747.10 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on August 12, 2025, with completion scheduled for August 13, 2025. This competitively awarded, firm fixed price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order valued at $3,869.18 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count supply) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $10,304.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFCQ4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $75,373.59 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price contract, awarded on August 11, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The contract contains no set-aside designation and was competitively awarded. Performance will be completed by August 12, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a comprehensive range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Gemtesa (mirabegron), a medication used to treat overactive bladder, reflects the company's role in supplying brand-name pharmaceuticals to support military healthcare programs worldwide through flexible contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $75.4k | 8/11/25 |